Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
about
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersThe biological effects and clinical implications of BRCA mutations: where do we go from here?Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast CancerAndrogen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisTargeting triple-negative breast cancer: optimising therapeutic outcomesBRCA1, a 'complex' protein involved in the maintenance of genomic stabilityRecent developments and translational aspects in targeted therapy for metastatic breast cancerCurrent advances in biomarkers for targeted therapy in triple-negative breast cancerExamining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamicsOpportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyReproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE studyCharacteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerCisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based studyGenotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instabilityA BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersFamily history of cancer associated with breast tumor clinicopathological featuresTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriersThe prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersThe PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient miceNovel therapeutic strategies in the treatment of triple-negative breast cancer.Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresBRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.SMAD4 is a potential prognostic marker in human breast carcinomas.ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approachesOncogenes and tumor suppressor genesmiR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
P2860
Q24654487-2DD4197D-2134-4023-A143-3C061C1043ABQ26741851-68A464C3-4D86-4FE2-B060-947EA0A1F6D5Q26744566-411DD4B3-9560-4881-8C40-E78275919D9CQ26823419-88A5BC99-2FA6-43F0-8E4F-3FD351DA5723Q26850892-70A34055-3B2A-4E3F-AAF9-5CFA288BA61CQ26853262-BCFD4A14-3E91-4942-BF2C-D863DC66B2A1Q28072755-F4D06F28-BBFA-4664-8E52-69CEAD5C33F1Q28074202-750308CB-9790-4AFE-9CBF-4CDBF679D2A4Q28383242-AAFC0403-F5C7-4B8F-AA96-62201E8FC7F0Q29248325-2B6E3BCC-D50E-41E2-99D3-9506F632EB86Q30432062-E307235C-B864-47AD-8529-D29FA13ED2E1Q30836057-F569215A-59E1-48B1-B14B-12821B0685AAQ33414349-667C9EAD-86AB-4CB9-9D36-94AC1D55ADE1Q33415281-EA816DCD-F4C7-483F-8DE9-A6959A9D5EE3Q33553668-4C9D835B-0F99-47AE-924F-85B6E20CEB19Q33557794-B9A0CC47-1047-42C9-A8C4-D411A677AEF3Q33584351-089B0C74-66EC-4217-926F-84BF3B7CD2EAQ33620683-8E6DEC7A-29F6-448A-87DF-EF3BA896E73CQ33624839-358A2157-5F17-4682-AEB6-D778D3AE14B0Q33739161-0692DA59-B1E4-4548-8378-12CD42697343Q33739351-44910F18-69A1-49AB-8065-F763C2F133AEQ33748161-F653A596-3BE0-4D9E-A619-BA86EFF25FDAQ33764057-EFECB2FF-D192-4FBF-9502-95A38188DB7DQ33769821-19C4131C-FC58-42FC-819A-BB9D27E59411Q33823472-0915C9BD-D787-4014-B6B6-7362BF77982BQ33826713-B0EEAE00-9D23-444E-883A-DDCC12F9BE49Q33863531-8DC9197B-25A6-4D32-B505-64F52A17A7ADQ33874466-D47CC775-004A-4A0A-8EFE-F387C1B25358Q33887682-CA3049DB-7004-4657-9A61-4C96C23DED28Q33892942-FC24831D-901E-4FE5-AA03-D8F0F4AB126DQ33894431-5ECD6B8B-8D1E-4A5A-A9A1-7B6338EAC8DCQ33896012-141A1293-1A32-4A36-B3FB-1C85A9AB6C5AQ34062522-4E9D03B8-4498-4720-BC6E-B4C6D22BDD38Q34062570-D1838F54-E6C1-4647-B118-9895B5D6E51CQ34077422-4FA8A2EF-ECF2-4D51-8B19-3B4842F97794Q34079958-EF585885-C7C7-4F91-A537-3C8A2A44C36BQ34119028-2D86C0B2-5AE7-4199-B0E9-5EF6B217579EQ34149922-4A663691-E708-4A0C-8996-086131FFF10FQ34157084-1317F32B-5910-48BE-B158-7156914550F2Q34216239-0672E796-4245-48E6-B7A7-6A6F20E612C1
P2860
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@en
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@nl
type
label
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@en
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@nl
prefLabel
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@en
Clinical and pathologic charac ...... d BRCA-negative breast cancer.
@nl
P2093
P356
P1476
Clinical and pathologic charac ...... nd BRCA-negative breast cancer
@en
P2093
Adriana Lopez
Ana Maria Gonzalez-Angulo
Banu K Arun
Constance T Albarracin
Deann P Atchley
Gabriel N Hortobagyi
Vicente Valero
P304
P356
10.1200/JCO.2008.16.6231
P407
P577
2008-09-01T00:00:00Z